Clinical Trial

Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia

Study acronym: SPRUCE
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will evaluate the efficacy and safety of zodasiran subcutaneous (sc) injection in participants 12 to \<18 years of age with genetically or clinically diagnosed homozygous familial hypercholesterolemia (HoFH) and low-density lipoprotein cholesterol (LDL-C) ≥116 milligrams per deciliter (mg/dL) on maximally tolerated lipid-lowering therapy.
Protocol Amendment History 1 change
minor Completion moved earlier: 2029-05 -> 2028-08 2026-05-30
Trial Details
NCT Number NCT07473843
Lead Sponsor Arrowhead Pharmaceuticals
Conditions Homozygous Familial Hypercholesterolemia
Enrollment 12 participants
Start Date 2026-08
Primary Completion 2028-07 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-05-29